Alba 
Sitemapcontactlogin 
HomePic.jpg
Technology Overview
Animation depicting the role of barrier function in disease pathology and Alba’s therapeutic approach through inhibition of increased paracellular permeability. View here »
IN THE NEWS

Alba-Sponsored Clinical Trials

For more information contact:

Alba Therapeutics Corporation is a Biopharmaceutical Company focused on the discovery, development and commercialization of therapeutics to treat autoimmune, immune mediated and inflammatory diseases. Alba’s technology provides the ability to transiently, physiologically and reversibly close or open the tight junctions of internal barriers such as the intestinal mucosa and pulmonary epithelia.  By altering paracellular permeability across these cell barriers, Alba seeks to develop therapeutic applications ranging from therapies for diseases associated with tight junction dysfunction and autoimmunity to vaccine adjuvancy and drug delivery. read more »

Tuesday, May 20, 2008
Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference Read more>> 
 

Friday, May 16, 2008
Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for Larazotide Acetate (AT1001) for the Treatment of Active Celiac Disease Read more>> 

Previous Press Releases
Copyright 2007 Alba Therapeutics Corporation. All Rights Reserved.Design: Round2